netbook
desktop
mobile
tablet-landscape
tablet
phone-landscape
phone
Research to Prevent Blindness

Eye Drops Could Clear Up Cataracts Using Newly Identified Chemical

Dogs develop age-related cataracts just like people.

RPB-supported researchers have partially reversed cataracts in dogs using eye drops and injections of a naturally occurring steroid in the human body. The discovery is pointing to an eye drop treatment for cataracts for people, and the impact will be global.

Cataracts are the leading cause of blindness worldwide, accounting for more than half of all cases. They most commonly occur over time, with age, when the transparent, tight protein structure of the human lens is disrupted, usually by protein aggregation caused by oxidative stress.

The National Eye Institute estimates that by age 80, more than half of all Americans either have a cataract or have had surgery to remove one.

The only treatment now available for cataracts is surgical removal of the natural lens and replacement with a plastic lens. While the surgery has very high success rates, in developed countries it contributes to higher healthcare costs. As populations age, estimates indicate that cataract surgeries will double in the next 20 years. Because cataract surgery emerges as an option later in life, delaying the development of the disease by as little as ten years might eliminate the need for nearly half of those surgeries.

Enter lanosterol, which the human body produces as a precursor to the creation of cholesterol. RPB-supported scientists identified a genetic mutation that interfered with the production of lanosterol in the cases of three children who had a severe, inherited cataract condition. In lab tests, lanosterol was shown to dissolve aggregated lens proteins.

"While we have yet to determine precisely how lanosterol is working, we are gratified that the treatment is working," said RPB resesarcher Dr. Kang Zhang, professor of ophthalmology and chief of ophthalmic genetics at UC San Diego.

Before testing can begin in humans, researchers will check the toxicity of lanosterol, then create an eye drop version of the drug, hopefully within a year.

Read the press release

 

 

Related News: Cataract, Top Story

scEYEnce campaign image

RPB and Partners Launch the scEYEnce Campaign

This new media campaign shines a spotlight on the powerful benefits of vision research.

Read More

 
David Williams

RPB and Association of University Professors of Ophthalmology Announce 2021 Recipient of RPB David F. Weeks Award for Outstanding Vision Research

David Williams, PhD, is recognized for ground-breaking contributions to the field of vision research.

Read More

 
Michael Chiang

Former RPB Grantee Dr. Michael Chiang Named Director of National Eye Institute

Dr. Chiang is a respected scientist, clinician and leader in vision research.

Read More

 
RPB logo

Research to Prevent Blindness Expands Career Development Award

RPB is increasing both the amount of funding and the number of awards funded through its flagship grant in order to better support early-career vision scientists.

Read More

 
RPB logo

Research to Prevent Blindness and Allergan Foundation Announce New Partnership to Support Early-Career Vision Researchers

The organizations announce new grants to increase funding for innovative research from early-career vision scientists.

Read More

 
RPB logo
Watch The Video

Research to Prevent Blindness Celebrates 60th Anniversary

For the past 60 years, RPB has funded groundbreaking research to prevent, treat and cure all conditions that damage or destroy sight.

Read More

 

Subscribe

Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.